Here Comes the “Antibody Boom”; (TSXV: $IPA.V) (OTC:
$IPATF) (TSX: $ZYME.TO) (NASDAQ: $SESN) (TSX: $PMN.TO)
Point Roberts, WA and Delta, BC - March 28, 2019
(Investorideas.com Newswire) Investorideas.com, a leading investor news
resource covering biotech and pharma stocks releases a snapshot looking at the
biopharmaceutical market and how monoclonal antibody research is gaining market
dominance.
GELifesciences.com,
talking about the Antibody boom says; “Many small and start-up companies are
developing new ideas as to how antibodies can be used. In many cases, these
companies will go on to be acquired by larger companies with the financial
capability to progress their ideas further. But with costs to establish
manufacturing capability in suitable existing buildings at not much more than
$10-15 M, this strategic opportunity lies within reach even for smaller
businesses. Despite steep competition and the need for significant investment,
the antibody space is a lucrative opportunity with various therapeutic avenues
that can be explored.”
Looking at some companies in the sector, Immunoprecise Antibodies Ltd. (TSXV: IPA) (OTC: IPATF), a therapeutic antibody discovery company, recently received a five-year Indefinite
Delivery/Indefinite Quantity (ID/IQ) subcontract from Leidos Biomedical
Research, Inc., which currently operates the Frederick National Laboratory for
Cancer Research for the National Cancer Institute (NCI). Under the subcontract,
IPA will discover and produce rabbit monoclonal antibodies using its
proprietary B-Cell Select platform.
Read this
in full at
The rabbit monoclonal antibodies discovered and produced
under this subcontract will be used in the key applications of immunohistochemistry
and immuno-Multiple Reaction Monitoring (immuno-MRM). The antibodies will be
generated for NCI’s Antibody Characterization Program.
Immuno-MRM is a leading-edge targeted mass spectrometry
technique that relies on antibodies to enrich peptides from complex biological
samples that are then quantified by mass spectrometry. Rabbit monoclonal
antibodies are highly sought after for this purpose because they exhibit high
specificity and bind their target with high affinity. Immuno-MRM is being used
to discover novel biomarkers and develop a new generation of clinical
diagnostic tests that could lead to improved cancer detection, diagnosis, and
treatment.
Zymeworks Inc. (NYSE: ZYME) (TSX: ZYME), a clinical-stage biopharmaceutical company developing
multifunctional therapeutics reported in January the achievement of a new development
milestone in its collaboration with Eli Lilly and Company. In accordance with
Zymeworks’ 2014 licensing and collaboration agreement with Lilly, Zymeworks
will receive a milestone payment of US$8.0 million for Lilly’s submission of an
IND application for an immuno-oncology bispecific antibody enabled by
Zymeworks’ proprietary Azymetric™ platform.
Sesen Bio, Inc. (NASDAQ: SESN), a late-stage clinical company advancing targeted fusion
protein therapeutics for the treatment of cancer recently reported positive preliminary efficacy data for the primary
endpoint of its ongoing Phase 3 registration trial, the VISTA Trial, of
Vicinium® for the treatment of patients with high-grade non-muscle
invasive bladder cancer (NMIBC) who have been previously treated with bacillus
Calmette-Guérin (BCG) and deemed BCG-unresponsive. The data reported show
clinically meaningful complete response rates in evaluable Carcinoma in situ patients at three, six, nine and
twelve months of follow-up in the trial consistent with the data in the
completed Phase 1 and Phase 2 clinical trials. Importantly, Vicinium continues
to be generally well-tolerated in treated patients.
ProMIS Neurosciences, Inc. (TSX: PMN) (OTC: ARFXF), a biotechnology company focused on the discovery and
development of antibody therapeutics targeting toxic oligomers implicated in
the development of neurodegenerative diseases will soon present data for new antibody candidates that
show stringent selectivity for the toxic forms of alpha-synuclein, considered a
root cause of Parkinson's disease.
ProMIS Neurosciences' Chief Scientific Officer, Dr. Neil Cashman will
discuss the preclinical data at a podium presentation on March 31 as well as
co-moderate the March 30 panel discussion on disease mechanisms in Alzheimer's
disease and Parkinson's disease.
ResearchandMarkets, in a biopharma market overview reported,
“The global biopharmaceuticals market was valued at USD 237,250.8 million in
2018, and is estimated to be valued at USD 388,997.3 million in 2024,
witnessing a CAGR of 8.59%.”
Within the related
segments, Monoclonal Antibodies are expected to gain the largest market size.
For investors
following medical technology and healthcare stocks, Investor Ideas has created a directory of biotech and medical
technology stocks
About Investorideas.com - News that Inspires
Big Investing Ideas
Investorideas.com is a recognized news source
publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about
cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water,
renewable energy and more . Investorideas.com original branded content includes
the daily Crypto
Corner and Podcast, Play by Play sports and
stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI Eye Podcast and column
covering developments in AI
Follow us on Social Media
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if required
but otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this news article
featuring (TSX VENTURE: IPA) (OTC PINK:
IPATF) a paid for service on Investorideas.com(third party) . Learn
more about costs and our services https://www.investorideas.com/News-Upload/
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Global investors must adhere to regulations of each country.
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment